Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

At week 16, 73.3% of gusacitinib-treated patients achieved reduction in hand eczema severity vs. 21.7% of those treated with placebo. Physician Global Assessment improvements were seen as early as ...

Asana is also developing an oral Janus kinase (JAK) and Spleen tyrosine kinase (SYK) inhibitor, gusacitinib, for immunology/dermatology indications such as chronic hand eczema and atopic dermatitis.

The company currently lists three candidates in its clinical pipeline, including a SYK/JAK inhibitor called gusacitinib in phase 3 development for chronic hand eczema. There’s also a sodium ...

The Libertas Bio pipeline now includes global rights to gusacitinib, an oral Phase 3-ready dual JAK/SYK inhibitor in development for chronic hand eczema, and ASN008, a Phase 2-ready topical sodium ...